학술논문
대한천식알레르기학회 알레르기비염 진료지침: 파트 1. 약물치료의 업데이트
KAAACI Allergic Rhinitis Guidelines: Part 1. Update in pharmacotherapy
KAAACI Allergic Rhinitis Guidelines: Part 1. Update in pharmacotherapy
Document Type
Article
Author
김민지 / Minji Kim; 강성윤 / Sung-yoon Kang; 양송이 / Song-i Yang; 이일환 / Il Hwan Lee; 류광희 / Gwanghui Ryu; 김미애 / Mi-ae Kim; 이상민 / Sang Min Lee; 김현정 / Hyun-jung Kim; 박도양 / Do-yang Park; 이용주 / Yong Ju Lee; 김동규 / Dong-kyu Kim; 김도현 / Do Hyun Kim; 전영준 / Young Joon Jun; 박상철 / Sang Chul Park; 김봉성 / Bong-seong Kim; 정수지 / Soojie Chung; 이현종 / Hyun Jong Lee; 김효빈 / Hyo-bin Kim; 최정희 / Jeong-hee Choi; 최길순 / Gil-soon Choi; 양현종 / Hyeon-jong Yang; 김수환 / Soo Whan Kim
Source
Allergy asthma & respiratory disease. Jul 30, 2023 11(3):117
Subject
Language
Korean
ISSN
2288-0402
Abstract
The prevalence of allergic rhinitis (AR) and the socioeconomic burden associated with the medical cost and quality of life of AR have progressively increased. Therefore, practical guidelines for the appropriate management of AR need to be developed based on scientific evidence considering the real-world environment, values, and preferences of patients and physicians. The Korean Academy of Asthma, Allergy and Clinical Immunology revised clinical guidelines for AR to address key clinical questions of the management of AR. Part 1 of the revised guideline covers the pharmacological management of patients with AR in Korea. Through a meta-analysis and a systematic review, we made 4 recommendations for AR pharmacotherapy, including intranasal corticosteroid (INCS)/intranasal antihistamine combination therapy, oral antihistamine/INCS combination therapy, leukotriene receptor antagonist treatment in AR patients with asthma, and prophylactic treatment for patients with pollen-induced AR. However, all recommendations are conditional because of the low or very low evidence of certainty. Well-designed and strictly executed randomized controlled trials are needed to measure and report appropriate outcomes. (Allergy Asthma Respir Dis 2023;11:117-125)